keine Finanzberatung

NVAX · Novavax, Inc.

Vaccine developer pivoting from selling shots to licensing its technology

Risiko 8/10 · HIGH RISK · vaccine-pivot biotech · $10.22 ▼ 1.16%Von KI geschrieben

Stand der Zahlen: · Quellen: öffentliche Markt-Aggregatoren

Kennzahlen

  • Price $10.22
  • Market cap $1.7B
  • P/E (ttm) n/a
  • Div yield none
  • 52-wk range $6.20 – $11.97

Wichtigste Risiken

  • Dependence on Sanofi partnership economics (Shareholders) — HIGH
  • Ongoing losses and fresh share issuance (Shareholders) — HIGH
  • Shrinking post-pandemic vaccine demand (Shareholders) — HIGH
  • Pipeline concentrated on the Matrix-M platform (Shareholders) — MED

Fazit

A cheaper, smarter version of a broken story — but a royalty-collector trading on partner goodwill is still a speculative biotech, not an investment-grade business.

Interaktive Analyse öffnen →

Recherche, keine Anlageberatung.

⚠️ Independent research for a video, not financial advice. Figures from public sources/aggregators, can be stale; risk scores are editorial estimates. Verify before relying on any of it.